Cargando…
Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5(NULL)-A20
We previously developed a refined, tumor-selective adenovirus, Ad5(NULL)-A20, harboring tropism ablating mutations in each major capsid protein, to ablate all native means of infection. We incorporated a 20-mer peptide (A20) in the fiber knob for selective infection via αvβ6 integrin, a marker of ag...
Autores principales: | Davies, James A., Marlow, Gareth, Uusi-Kerttula, Hanni K., Seaton, Gillian, Piggott, Luke, Badder, Luned M., Clarkson, Richard W. E., Chester, John D., Parker, Alan L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151668/ https://www.ncbi.nlm.nih.gov/pubmed/34066836 http://dx.doi.org/10.3390/v13050864 |
Ejemplares similares
-
Precision virotherapies: Coming soon
por: Uusi-Kerttula, Hanni, et al.
Publicado: (2018) -
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10
por: Bates, Emily A., et al.
Publicado: (2022) -
Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies
por: Uusi-Kerttula, Hanni, et al.
Publicado: (2016) -
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
por: Uusi-Kerttula, Hanni, et al.
Publicado: (2015) -
Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies
por: Uusi-Kerttula, Hanni, et al.
Publicado: (2015)